CAR-T(CAR-T)细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T(CAR-T)细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:Co-opting signalling molecules enables logic-gated control of CAR T cells.
Co-opting signalling molecules enables logic-gated control of CAR T cells.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
尽管嵌合抗原受体(CAR)T细胞改变了B细胞恶性肿瘤的治疗格局,但靶上非肿瘤毒性的风险阻碍了其在实体瘤中的开发,因为多数靶抗原也表达于正常细胞。研究者曾尝试为CAR-T 细胞应用布尔逻辑门控以预防毒性,但真正安全有效的逻辑门控CAR仍未实现。本文介绍一种CAR工程策略,以胞内近端T细胞信号分子取代传统CD3结构域。
我们显示,某些近端信号CAR(如ZAP-70 CAR)可激活T细胞并在体内清除肿瘤,同时绕过包括CD3在内的上游信号蛋白。ZAP-70的主要作用是磷酸化LAT和SLP-76,二者形成信号传递支架。
我们利用LAT和SLP-76的协同作用,设计了逻辑门控胞内网络(LINK)CAR。这是一种快速、可逆的布尔逻辑“与”门控CAR-T 细胞平台,在疗效和防止靶上非肿瘤毒性方面均优于其他系统。LINK CAR将扩大CAR-T 细胞可靶向分子的范围,并使这类强效治疗药物可用于实体瘤、自身免疫病和纤维化等多种疾病。
此外,本研究还表明,细胞内部信号机制可被重新设计为表面受体,从而为细胞工程开辟新方向。
Although chimeric antigen receptor (CAR) T cells have altered the treatment landscape for B cell malignancies, the risk of on-target, off-tumour toxicity has hampered their development for solid tumours because most target antigens are shared with normal cells 1,2 . Researchers have attempted to apply Boolean-logic gating to CAR T cells to prevent toxicity 3-5 ; however, a truly safe and effective logic-gated CAR has remained elusive 6 .
Here we describe an approach to CAR engineering in which we replace traditional CD3 domains with intracellular proximal T cell signalling molecules.
We show that certain proximal signalling CARs, such as a ZAP-70 CAR, can activate T cells and eradicate tumours in vivo while bypassing upstream signalling proteins, including CD3 . The primary role of ZAP-70 is to phosphorylate LAT and SLP-76, which form a scaffold for signal propagation.
We exploited the cooperative role of LAT and SLP-76 to engineer logic-gated intracellular network (LINK) CAR, a rapid and reversible Boolean-logic AND-gated CAR T cell platform that outperforms other systems in both efficacy and prevention of on-target, off-tumour toxicity. LINK CAR will expand the range of molecules that can be targeted with CAR T cells, and will enable these powerful therapeutic agents to be used for solid tumours and diverse diseases such as autoimmunity 7 and fibrosis 8 .
In addition, this work shows that the internal signalling machinery of cells can be repurposed into surface receptors, which could open new avenues for cellular engineering.
在 PubMed 查看 → 出版商原文(DOI) 全文 PDF(PMC)· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →
MEMBER ACCOUNT
登录成功会直接打开下一页。